Black Diamond Therapeutics(BDTX) - 2025 Q3 - Quarterly Results

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update CAMBRIDGE, MA, November 6, 2025 (GLOBE NEWSWIRE) – Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update. "We are looking forward to sharing a clinical update later thi ...